{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(2)"],"submitter":["Wiseman CL"],"pubmed_abstract":["<h4>Background</h4>SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.<h4>Methods</h4>We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by lowdose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SVBR- 1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.<h4>Results</h4>Treatment was generally safe and well tolerated. Immune responses"],"journal":["Recent patents on anti-cancer drug discovery"],"pagination":["224-240"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10009895"],"repository":["biostudies-literature"],"pubmed_title":["Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response."],"pmcid":["PMC10009895"],"pubmed_authors":["Williams WV","Dozio V","Macuchova E","Sunkari VG","Lacher MD","Kharazi A","Hashwah H","Wiseman CL","Galeas JL"],"additional_accession":[]},"is_claimable":false,"name":"Regression of Breast Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual Property and Immune Markers of Response.","description":"<h4>Background</h4>SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.<h4>Methods</h4>We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects. Inoculations were preceded by lowdose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SVBR- 1-GM inoculation sites. We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.<h4>Results</h4>Treatment was generally safe and well tolerated. Immune responses","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-14T03:19:25.617Z","creation":"2025-04-06T16:28:03.927Z"},"accession":"S-EPMC10009895","cross_references":{"pubmed":["35593340"],"doi":["10.2174/1574892817666220518123331"]}}